Pathology of the digestive tract and liver with COVID-19

Яковенко Э. П.; Яковенко А. В.; Иванов А. Н.; Агафонова Н. А.

Статья

Патология пищеварительного тракта и печени при COVID-19

Яковенко Э. П., Яковенко А. В., Иванов А. Н., Агафонова Н. А.,

2020

https://doi.org/10.31146/1682-8658-ecg-176-4-19-23

Поражение желудочно-кишечного тракта и печени выявляется у более половины пациентов с COVID-19. При этом заболевание может начинаться с гастроэнтерологических проявлений, к которым впоследствии присоединяются респираторные симптомы. Наличие поражений желудочно-кишечного тракта и печени у больных COVID-19 ухудшает прогноз заболевания и повышает риск смертности. Механизмы повреждения пищеварительной системы многообразны: прямой цитолитический эффект вируса на клетки–мишени, на поверхности которых имеются рецепторы для SARS-CoV-2, действие компонентов системного воспаления, иммунологические и лекарственные повреждения. В терапии больных COVID-19 с гастроэнтерологическими расстройствами и нарушением функции печени перспективным направлением является исследование ребамипида и урсодеоксихолевой кислоты.

Цитирование

Список литературы

1. Phelan AL, Katz R, Gostin LO. The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance. JAMA. 2020;323(8):709–710.

2. Wu Y, Ho W, Huang Y, et al. SARS-CoV-2 is an appropriate name for the new coronavirus. Lancet. 2020; Mar 21;395(10228):949–950.

3. Markus Hoffmann et al.SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020; 181, 1–10.

4. Hao Xu1, Liang Zhong1, Jiaxin Denget al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. International Journal of Oral Science. 2020; 12:8.

5. Wang К, Chen W., Zhou Y-S.et al. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. doi: https://doi.org/10.1101/2020.03.14.988345.

6. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; Mar;579(7798):270–273.

7. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13.

8. Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. https://www.naturalnews.com/fi les/Clinical-characteristics-of-2019-novel-coronavirus-infection-in-China.pdf.

9. Wang F-S, Zhang C. What to do next to control the 2019-nCoV epidemic? Lancet 2020; 395: 391–93.

10. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.

11. Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020; Mar 5;382(10):929–936.

12. To KK, Tsang OT, Chik-Yan Yip C, et al. Consistent detection of 2019 novel coronavirus in saliva [published on February 12, 2020]. Clin Infect Dis. 2020 Feb 12: ciaa149.

13. Han, C., Duan С., Zhang S. Digestive Symptoms in COVID-19 Patients with Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes. https://journals.lww.com/ajg/Documents/COVID19_Han_et_al_AJG_Preproof.pdf.

14. Gu J, Han B, Wang J. COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission, Gastroenterology (2020), doi: https://doi.org/10.1053/j.gastro.2020.02.054.

15. Chai X, Hu L, Zhang Y et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. BioRxiv 2020 February 4. doi: 10.1101/2020.02.03.931766.

16. Cai Q, Huang D, Yu H. et al. Characteristics of liver tests in COVID-19 patients, Journal of Hepatology (2020), doi: https://doi.org/10.1016/j.jhep.2020.04.006.

17. Fan Z, Chen L, Li J, et al. Clinical features of COVID-19 related liver damage. MedRxiv 2020 February 28. doi: 10.1101/2020.02.26.20026971. [Epub ahead of print].

18. Xu L, Liu J, Lu M, et al. Liver injury during highly pathogenic human coronavirus infections. Liver Int 2020 March 14. doi: 10.1111/liv.14435. [Epub ahead of print].

19. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054–1062.

20. Boettler T., Newsome P. N., Mondelli M. U. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID Position Paper. https://doi.org/10.1016/j.jhepr.2020.100113

21. Xiao F, Tang M, Zheng X et al. Evidence for gastrointestinal infection of SARS-CoV-2, Gastroenterology (2020), https://doi.org/10.1053/j.gastro.2020.02.055.

22. Zhang H, Kang ZJ, Gong HY, et al. The digestive system is a potential route of 2019-n Cov infection: a bioinformatics analysis based on single-cell transcriptomes. Preprint. Posted. online January 30, 2020. bioRxiv 927806. doi: 10.1101/2020.01.30.927806.

23. Budden KF, Gellatly SL, Wood DL, et al. Emerging pathogenic links between microbiota and the gut-lung axis. Nat Rev Microbiol. 2017;15:55–63.

24. He Y, Wen Q, Yao F, Xu D, Huang Y, Wang J. Gut-lung axis: The microbial contributions and clinical implications. Crit Rev Microbiol. 2017;43:81–95.

25. Li M, Wang B, Zhang M, et al. Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci U S A. 2008;105:2117–22.

26. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 2020; published online March 4. https://www.researchgate.net/publication/339783197_Liver_injury_in_COVID-19_management_and_challenges.

27. Liu Q, Wang R, Qu G et al. Macroscopic autopsy findings in a patient with COVID-19. J Forensic Med 2020; 36: 1–3 (in Chinese).

28. Arakawa T, Higuchi K, Fujiwara Y et al. 15th Anniversary of Rebamipide: Looking Ahead to the New Mechanisms and New Applications. Dig Dis Sci. 2005; 50(1): S3-S11. doi:10.1007/s10620–005–2800–9.

29. Genta R. M. Review article: the role of rebamipide in the management of infl ammatory disease of the gastrointestinal tract Aliment Pharmacol Ther 2003; 18 (Suppl. 1): 8–13.

30. Urita, Yoshihisa & Watanabe, et al. Rebamipide Improves Salivary Gland Function and Saliva Transit to the Distal Esophagus: 48. American Journal of Gastroenterology. 2007. 102. S135. doi:10.14309/00000434–200709002–00048.

31. Lee SY et al. The inhibitory effects of rebamipide on cigarette smoke-induced airway mucin production. Respir Med. 2006 Mar;100(3):503–11.

32. Gohil P et al. Preliminary studies on the effect of rebamipide against the trypsin and egg-albumin induced experimental model of asthma. Acta Pharm. 2011 Dec;61(4):427–33.

33. Ling Xu Jia Liu Mengji Lu et al. Liver injury during highly pathogenic human coronavirus infections Liver International. 2020;00:1–7. doi.org/10.1111/liv.14435.

34. Fangfang Niu et al. Ursodeoxycholic Acid Stimulates Alveolar Fluid Clearance in LPS-induced Pulmonary Edema via ALX/cAMP/PI3K Pathway J Cell Physiol. 2019 Nov;234(11):20057–20065.

35. Willart MA van Nimwegen M, Gref horst A, et al. Ursodeoxycholic acid suppresses eosinophilic airway infl ammation by inhibiting the function of dendritic cells through the nuclear farnesoid X receptor. Allergy. 2012 Dec;67(12):1501–10. doi: 10.1111/all.12019. Epub 2012 Sep 25.

Источник

Версии

1. Version of Record от 2020-06-22

Метаданные

Об авторах

Яковенко Э. П.
ФГАОУ ВО РНИМУ им. Н. И. Пирогова Минздрава России
Яковенко А. В.
ФГАОУ ВО РНИМУ им. Н. И. Пирогова Минздрава России
Иванов А. Н.
ФГАОУ ВО РНИМУ им. Н. И. Пирогова Минздрава России
Агафонова Н. А.
ФГАОУ ВО РНИМУ им. Н. И. Пирогова Минздрава России

Предметная рубрика

COVID-19

Название журнала

Experimental and Clinical Gastroenterology

Страницы

19-23

Тип документа

journal article

Тип лицензии Creative Commons

CC BY

Правовой статус документа

Свободная лицензия

Источник

elpub

Поиск по репозиторию

Статья

Патология пищеварительного тракта и печени при COVID-19

Похожие публикации

Источник

Версии

Метаданные